Can a shorter radiation course tame relapsed lymphoma?

NCT ID NCT05019976

Ongoing Symptom relief Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a shorter course of radiation (over 2-3 weeks instead of the usual 5-6 weeks) is safe for people with Hodgkin or Non-Hodgkin lymphoma that has returned or not responded to treatment. About 30 participants will receive different radiation doses to find the safest shortened schedule. The goal is to reduce treatment burden while still controlling the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy
What this could lead to: If successful, this could offer a shorter, more convenient radiation schedule for people with lymphoma that is still safe and effective.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to everyone. The main goal is safety, not yet proving the shorter course works as well as the standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma lymphoma neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.